Navigation Links
Vigabatrin in Medical News

Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

- Study Demonstrates Statistically Significant Efficacy vs. Placebo - - Trial Conducted Under Direction of New York University School of Medicine - CORAL GABLES, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ), a...

Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Taurine: Key to the visual toxicity of an anti-epileptic drug for children?

... vigabatrin (Sabril), first intention molecule for the treatme...d strategies for limiting it. They have shown that vigabatrin provokes a marked decrease in the blood level in a...validation of an alternative treatment associating vigabatrin and taurine, this will necessitate several years o...

Controversial medication may decrease spasms for infants with epilepsy

...Finland February 02, 2009 The antiepileptic drug vigabatrin (VGB) has been shown to be one of the best treatme...and produces more reliable results in children. vigabatrin treatment began at a mean age of 7.6 months, and t...ents. "Our results may encourage doctors to use vigabatrin to treat infantile spasms as the risk for visual f...

Hope for treating relapse to methamphetamine abuse

...(DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seek...nvironment. Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where...he research team. "This animal study suggests that vigabatrin could potentially prevent human methamphetamine ad...

Diet may eliminate spasms for infants with epilepsy

...trophy, and visual field constriction. ACTH, though it is effective in 60-70 percent of cases, also costs more than $80,000 for a one-month supply and vigabatrin is not currently available in the U.S. Both drugs have about a 30-40 percent recurrence rate of spasms as well. Other therapies are not yet proven. ...

Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance

... are undertaking to stem the cycle of drug addiction through treatment with vigabatrin is continuing to garner interest in the market. We were especially pleased ...of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- ...

Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results

...ghts to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This ind...
Vigabatrin in Medical Technology

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

CORAL GABLES, Fla., Aug 21 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

...ished clinical and non-clinical results evaluating vigabatrin as a treatment for cocaine addiction. Catalyst ex... in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions an.... The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

... far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that...bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. In Decembe...I double-blind, placebo-controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence du...

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

...lyst announced positive initial top-line results from a 103-patient, investigator-initiated Phase II double-blind, placebo- controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this study will be rep...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

...lence study demonstrating that CPP-109 (Catalyst's vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis. These data p... pre-clinical and clinical literature on Sabril. vigabatrin has been marketed over the past decade in more tha...
Vigabatrin in Biological Technology

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

...es that operate under the NIH umbrella, for future vigabatrin addiction trials and to provide a portion of the r...domized, Double-Blind, Placebo-Controlled Trial of vigabatrin for the Treatment of Cocaine Dependence in Mexican...nd Eugene M. Laska, Ph.D. The paper suggests that vigabatrin may be effective in the treatment of cocaine addic...

Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice

... license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive-compulsive di...in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food &...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results

...any has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...

Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results

...okhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents p...

Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement

...from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-r...
Other Tags
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
(Date:4/17/2014)... Orange, NJ. April 16, 2014. Kessler Foundation has ... $1.8 million from the Department of Defense Spinal ... is principal investigator for the randomized, double-blinded, controlled, ... improve bone and muscle strength after spinal cord ... Performance & Engineering Research at Kessler Foundation. Two ...
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... Down syndrome - or trisomy 21 - is the ... from a chromosomal abnormality where cells of affected individuals ... the human genome). A study conducted by Stylianos Antonarakis ... and Development at the University of Geneva (UNIGE) Faculty ... on how the extra chromosome 21 upsets the equilibrium ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
Other Contents